Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multiple Ascending Dose Study
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AZD7268 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD7268 | Drug | Capsule, Oral, QD |
| |
| AZD7268 |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the safety and tolerability of AZD7268 when given orally in multiple ascending doses to healthy male subjects and female subjects of non-childbearing potential. | Safety assessments are made at each visit, at least daily, during the study. |
| Measure | Description | Time Frame |
|---|---|---|
| To characterize the pharmacokinetics of AZD7268 in plasma. | Serial blood samples for pharmacokinetic analysis will be collected on Days 1,2,3 and Days 9, 10, and 11 of the study. Additional pharmacokinetic samples will be collected on Days 6, 7, and 8 |
Not provided
Inclusion Criteria:
Provision of Informed Consent
Healthy male subjects and female subjects (of non-child bearing potential)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sylvan Hurewitz, M.D. | AstraZeneca Clinical Pharmacology Unit, US | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Philadelphia | Pennsylvania | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Capsule, Oral, BID |
|
| Placebo | Drug | Capsule, Oral BID |
|